Brief: GSK Says Ris-Rez Reduces Risk Of Death By 54% In Relapsed Small Cell Lung Cancer In China
14/09/2026 07:24
BRIEF-GSK Says Ris-Rez Reduces Risk Of Death By 54% In Relapsed Small Cell Lung Cancer In China Sept 14 (Reuters) - GSK plc GSK.L:
GSK PLC - RIS-REZ POSITIVE PH 3 OS LUNG CANCER DATA IN CHINA
GSK - RIS-REZ MEDIAN OVERALL SURVIVAL 18.5 MONTHS VERSUS 10.3 MONTHS WITH TOPOTECAN
GSK - RIS-REZ REDUCES RISK OF DEATH BY 54% IN RELAPSED SMALL CELL LUNG CANCER IN CHINA
GSK - RIS-REZ ACHIEVES LONGER SURVIVAL WITH FEWER SEVERE SIDE EFFECTS VERSUS TOPOTECAN
GSK - RIS-REZ MEDIAN PROGRESSION-FREE SURVIVAL 7.2 MONTHS VERSUS 3.0 MONTHS WITH TOPOTECAN
GSK - RIS-REZ OBJECTIVE RESPONSE RATE 58.3% VERSUS 12.6% WITH TOPOTECAN
Source text: ID:nRSN5431Ua
Further company coverage: GSK.L
((Reuters.Briefs@thomsonreuters.com;))